401 related articles for article (PubMed ID: 28162854)
1. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
2. Serious infections among a large cohort of subjects with systemically treated psoriasis.
Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
[TBL] [Abstract][Full Text] [Related]
3. The risk of melanoma and hematologic cancers in patients with psoriasis.
Reddy SP; Martires K; Wu JJ
J Am Acad Dermatol; 2017 Apr; 76(4):639-647.e2. PubMed ID: 27876302
[TBL] [Abstract][Full Text] [Related]
4. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
5. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
[TBL] [Abstract][Full Text] [Related]
6. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
7. Personal history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States: A population-based cohort study.
Dai H; Li WQ; Qureshi AA; Han J
J Am Acad Dermatol; 2016 Oct; 75(4):731-735. PubMed ID: 27436157
[TBL] [Abstract][Full Text] [Related]
8. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.
Katz KA; Marcil I; Stern RS
J Invest Dermatol; 2002 Jun; 118(6):1038-43. PubMed ID: 12060400
[TBL] [Abstract][Full Text] [Related]
10. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A; Lebwohl M; Langley RG; Rowland K; Yang YW; Chan D; Miller M; You Y; Yu J; Thaҫi D; Foley P; Papp KA
J Am Acad Dermatol; 2023 Aug; 89(2):274-282. PubMed ID: 37019386
[TBL] [Abstract][Full Text] [Related]
11. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
[TBL] [Abstract][Full Text] [Related]
12. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
Kimball AB; Schenfeld J; Accortt NA; Anthony MS; Rothman KJ; Pariser D
Br J Dermatol; 2015 Nov; 173(5):1183-90. PubMed ID: 26265015
[TBL] [Abstract][Full Text] [Related]
13. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
Chakravarty EF; Michaud K; Wolfe F
J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
[TBL] [Abstract][Full Text] [Related]
14. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
15. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota.
Brewer JD; Shanafelt TD; Khezri F; Sosa Seda IM; Zubair AS; Baum CL; Arpey CJ; Cerhan JR; Call TG; Roenigk RK; Smith CY; Weaver AL; Otley CC
J Am Acad Dermatol; 2015 Feb; 72(2):302-9. PubMed ID: 25479909
[TBL] [Abstract][Full Text] [Related]
16. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients.
Funk-Debleds P; Ducroux E; Guillaud O; Ursic-Bedoya J; Decullier E; Vallin M; Euvrard S; Pageaux GP; Boillot O; Dumortier J
J Am Acad Dermatol; 2018 Jul; 79(1):84-91. PubMed ID: 29307647
[TBL] [Abstract][Full Text] [Related]
17. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
[TBL] [Abstract][Full Text] [Related]
18. The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network.
Chiesa Fuxench ZC; Shin DB; Ogdie Beatty A; Gelfand JM
JAMA Dermatol; 2016 Mar; 152(3):282-90. PubMed ID: 26676102
[TBL] [Abstract][Full Text] [Related]
19. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
Paul CF; Ho VC; McGeown C; Christophers E; Schmidtmann B; Guillaume JC; Lamarque V; Dubertret L
J Invest Dermatol; 2003 Feb; 120(2):211-6. PubMed ID: 12542524
[TBL] [Abstract][Full Text] [Related]
20. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]